Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial crawled date : 2021 - 12 - 01 save search
STAG Industrial Announces Completion Of Largest Rooftop Community Solar Project In The Country
Published: 2021-12-01 (Crawled : 22:00) - stagindustrial.com
STAG | $34.93 1.6% 0.0% 1.5M
|
Finance
|
| O: 0.46%
H: 1.45%
C: -0.51%
solar trial
Amgen Announces Positive Top-Line Results From Otezla® (apremilast) Phase 3 DISCREET Study In Moderate To Severe Genital Psoriasis
Published: 2021-12-01 (Crawled : 22:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 3.7%
H: 3.74%
C: -0.91%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.78%
H: 2.59%
C: 0.18%
psoriasis positive results phase 3 topline
180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal Presents Keynote Address at the 2021 International Dupuytren Symposium, Including Top Line Data From the Phase 2b Clinical Trial
Published: 2021-12-01 (Crawled : 20:00) - globenewswire.com
ATNF | $1.87 2.19% 2.14% 20K
|
|
| O: -15.64%
H: 2.81%
C: -9.39%
phase 2 phase 2b trial life science topline symposium
INmune Bio, Inc. Announces Two Presentations at the 2021 British Society of Immunology Congress and Provides 119-day data on First patient in MDS trial.
Published: 2021-12-01 (Crawled : 15:30) - biospace.com/
INMB | $8.33 -5.34% -5.64% 69K
|
Health Technology
|
| O: 1.71%
H: 0.92%
C: -9.79%
trial presentation immunology
Lynk Pharmaceuticals Announced First Patient Dosed in Phase II Clinical Study of LNK01001
Published: 2021-12-01 (Crawled : 15:30) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -1.03%
H: 2.04%
C: 0.76%
The Lancet Psychiatry Publishes Results from ADVANCE Study Evaluating Pimavanserin Treatment for Negative Symptoms of Schizophrenia
Published: 2021-12-01 (Crawled : 15:30) - biospace.com/
ACAD | $16.82 -1.47% -1.49% 3.5M
|
Health Technology
|
| O: -0.99%
H: 5.1%
C: -0.58%
treatment schizophrenia results negative lancet
Selecta Biosciences and Sobi Announce Completion of Enrollment in DISSOLVE Phase 3 Study Evaluating SEL-212 for Chronic Refractory Gout
Published: 2021-12-01 (Crawled : 15:00) - biospace.com/
SELB 4 | $0.8812 -8.0% 2.12% 0
|
Health Technology
|
| O: 5.86%
H: 2.93%
C: -4.89%
chronic refractory gout bioscience phase 3 enroll sel-212
Harmony Biosciences Announces Plans To Initiate Phase 3 Clinical Trial For Treatment Of Idiopathic Hypersomnia
Published: 2021-12-01 (Crawled : 15:00) - biospace.com/
HRMY | $29.42 1.34% 1.33% 390K
|
Health Technology
|
| O: 5.34%
H: 4.4%
C: -1.0%
treatment trial bioscience phase 3
STMicroelectronics Streamlines Machine-Learning Software Development for Connected Devices and Industrial Equipment with Upgrades to NanoEdge™ AI Studio
Published: 2021-12-01 (Crawled : 14:30) - globenewswire.com
STMEF | $40.836 -5.77% 2K
|
Electronic Technology
|
| O: 3.39%
H: 1.38%
C: -0.53%
STM | $38.6 -2.55% 0.0% 4M
|
Electronic Technology
|
| O: 3.77%
H: 1.57%
C: -1.77%
electronics device trial software
Oncotelic Initiates Phase 2 Trial Evaluating OT-101 in Combination with KEYTRUDA® for Mesothelioma
Published: 2021-12-01 (Crawled : 14:30) - globenewswire.com
OTLC | $0.042 -44.63% 100K
|
Manufacturing
|
| O: 1.48%
H: 20.44%
C: 5.84%
phase 2 trial keytruda
CSW Industrials Names Bobby Griffin to Board of Directors, Enhancing Diversity, Independence, and Experience
Published: 2021-12-01 (Crawled : 14:00) - globenewswire.com
ROK | $269.96 -1.29% 0.0% 1.2M
|
Producer Manufacturing
|
| O: 0.8%
H: 1.14%
C: -2.53%
FLS | $45.8 0.37% 0.0% 670K
|
Producer Manufacturing
|
| O: 0.36%
H: 1.24%
C: -3.62%
CBRE | $84.9 -0.28% 0.0% 1.8M
|
Finance
|
| O: 0.7%
H: 1.56%
C: -2.43%
CSWI | $232.19 -0.77% -0.77% 150K
|
Process Industries
|
| O: -1.53%
H: 1.65%
C: -3.05%
trials trial
Sobi and Selecta Biosciences announce completion of enrolment in DISSOLVE Phase 3 study evaluating SEL-212 for chronic refractory gout
Published: 2021-12-01 (Crawled : 14:00) - biospace.com/
SELB 4 | $0.8812 -8.0% 2.12% 0
|
Health Technology
|
| O: 5.86%
H: 2.93%
C: -4.89%
bioscience phase 3 enroll sel-212 chronic refractory gout
Virios Therapeutics Achieves Over 50% Enrollment Milestone in its Phase 2b Clinical Trial for Fibromyalgia
Published: 2021-12-01 (Crawled : 13:30) - biospace.com/
VIRI | $0.4393 -2.36% -2.41% 59K
|
Health Technology
|
| O: 14.52%
H: 0.0%
C: -8.15%
phase 2 phase 2b fibromyalgia trial therapeutics enroll milestone
Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis
Published: 2021-12-01 (Crawled : 13:30) - biospace.com/
VRTX | News | $394.43 0.24% 0.24% 1.3M
|
Health Technology
|
| O: 3.24%
H: 5.25%
C: 4.81%
phase 2 media positive results positive results sclerosis
SAB Biotherapeutics Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus
Published: 2021-12-01 (Crawled : 13:30) - biospace.com/
SABS | $4.46 0.22% 890
|
|
| O: 1.77%
H: 10.82%
C: 3.02%
phase 2 therapeutics influenza iot sab-176 diversitab infections phase 2b
Rallybio Reports Positive Data in Its Clinical Program for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Published: 2021-12-01 (Crawled : 13:00) - biospace.com/
RLYB | News | $1.75 4.79% 4.57% 310K
|
|
| O: -2.17%
H: 0.0%
C: -12.62%
positive
G1 Therapeutics Initiates Phase 2 Trial to Support the Antitumor Mechanism of Action (MOA) of Trilaciclib in the Tumor Microenvironment
Published: 2021-12-01 (Crawled : 12:30) - globenewswire.com
GTHX | $4.12 -1.2% -1.21% 730K
|
Health Technology
|
| O: 6.41%
H: 0.0%
C: 0.0%
phase 2 trilaciclib trial therapeutics
COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
Published: 2021-12-01 (Crawled : 12:30) - globenewswire.com
CMPS | $8.35 -0.83% -0.84% 370K
|
Health Technology
|
| O: 6.29%
H: 0.0%
C: -8.02%
treatment comp360 trial positive results positive therapy results depression psilocybin
USPh Announces Acquisition of Industrial Injury Prevention Services Company
Published: 2021-12-01 (Crawled : 12:00) - usph.com
USPH 4 | $99.09 1.64% 0.0% 62K
|
Health Services
|
| O: 1.02%
H: 0.39%
C: -4.78%
acquisition trial
Insights on the Clinical Trial Equipment & Ancillary Solutions Global Market to 2028 - by Product, Phase and Region
Published: 2021-12-01 (Crawled : 11:00) - prnewswire.com
TMO | News | $544.78 0.6% 0.0% 1.7M
|
Health Technology
|
| O: -1.55%
H: 0.47%
C: -1.34%
trial
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.